News

Derma Sciences has finalized a three-year contract with a leading global healthcare products company to produce finger bandages. The agreement is expected to generate approximately $15 million in

The Alcon’s Independent Director Committee, in response to comments made by Novartis, stated its belief that Alcon has established certain important protections for the benefit of its minority

Boston Scientific has completed enrollment in its Maps clinical trial, which is studying the coiling of intracranial aneurysms. This prospective, randomized trial commenced enrollment in 2007 and has

Excaliard Pharmaceuticals (Excaliard) has initiated three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and

Konica Minolta Sensing Americas (KMSA) has launched color measurement instrument, the CM-5 Spectrophotometer in the US. The CM-5 is a full featured, accurate and a totally standalone instrument

VBL Therapeutics has initiated Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201, orally-administered immune response modifier expected to

Laureate Pharma (Laureate) and Selexis have continued their collaboration via a joint-marketing relationship. The expanded relationship provides streamlined access to a set of contract services to both the

Dainippon Sumitomo Pharma America (DSPA), a US subsidiary of Dainippon Sumitomo Pharma (DSP), has submitted a New Drug Application (NDA) to the FDA for Lurasidone, an investigational atypical

BioVectra has signed agreements with Sandoz, whereunder Sandoz will commercialise and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere developed